Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy

2.1 Oral azacitidine (Onureg, Celgene, a Bristol Myers Squibb company) is indicated 'as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT)'.

2.2 The dosage schedule is available in the summary of product characteristics for oral azacitidine.

2.3 The list price for oral azacitidine is £5,867 for a 200‑mg or 300‑mg pack of 7 tablets (excluding VAT; price confirmed by the company). The company has a commercial arrangement. This makes oral azacitidine available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.